Description:
H.R. 1352, Increasing Access to Biosimilars Act of 2023 As ordered reported by the House Committee on Energy and Commerce on December 6, 2023 By Fiscal Year, Millions of Dollars20242024-20292024-2034Direct Spending (Outlays)0233227Revenues000Increase or Decrease (-) in the Deficit0233227Spending Subject to Appropriation (Outlays)00not estimatedIncreases net direct spending in any of the four consecutive 10-year periods beginning in 2035?NoStatutory pay-as-you-go procedures apply?YesMandate EffectsIncreases on-budget deficits in any of the four consecutive 10-year periods beginning in 2035?NoContains intergovernmental mandate?NoContains private-sector mandate?NoThe bill wouldDirect the Department of Health and Human Services to implement a demonstration project that would increase Medicare payment rates for biosimilar products covered under Medicare Part BEstimated budgetary effects would mainly stem fromIncreasing Medicare payment rates for biosimilarsPreventing increases in cost sharing for beneficiariesAreas of significant uncertainty includePredicting payment rates under the demonstrationIdentifying which biosimilars would be used in the demonstrationProjecting effects on biosimilar use and prices after the demonstration
« Return to search CBO reports
